Procarta Biosystems has received an award from CARB-X, potentially worth $9.2 million, for the development of antibiotic precision medicines.
Procarta Biosystems, a biotech company based in the United Kingdom, has received an award from global non-profit partnership, CARB-X, potentially worth $9.2 million, to be used for the development of antibiotic precision medicines.
In a Sep. 17, 2019 press release, the UK-based biotech revealed that it will be granted an initial non-dilutive funding of $2.2 million through the CARB-X award and with the opportunity of gaining a further $7 million should certain milestones be met. Procarta will use the money to advance its proprietary oligonucleotide-based antimicrobial platform and will specifically target infections caused by Gram-negative ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens.
“This new award from CARB-X recognizes the value of the novel modalities in our pipeline and their potential to precipitate a paradigm shift in antimicrobial treatments,” said Andrew Lightfoot, chief executive officer of Procarta in a press release. “We are delighted to have support from CARB-X recognizing the importance of developing new antibiotics to combat antimicrobial resistance.”
“This award from CARB-X follows closely on a €1.5-million (US$1.7-million) investment from the Novo Holdings REPAIR Impact Fund. Together, these new funds will be used to progress our lead asset, PRO-202, and to develop our proprietary drug discovery platform to build a pipeline of antimicrobial agents to cover the ESKAPE pathogens,” Lightfoot added.
Source: Procarta Biosystems
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.